Also known as: Point Biopharma
POINT Biopharma Global is a radiopharmaceutical company focused on developing and commercializing radioligands for cancer. It describes a platform combining therapeutic assets, isotope expertise, and manufacturing capabilities to advance precision oncology. The company was publicly listed on Nasdaq under PNT in 2021 and reports headquarters in Indianapolis.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
Radiopharmaceuticals are emerging as a promising therapeutic class in oncology, with theranostic approaches combining diagnostics and treatment gaining particular attention. Major pharmaceutical companies have invested billions in acquisitions while venture financing reached record levels.
